Jabeen Kausar, Shakoor Sadia, Malik Faisal, Hasan Rumina
Department of Pathology & Microbiology, Aga Khan University, Stadium Road, PO Box 3500, Karachi, Pakistan.
Int J Mycobacteriol. 2015 Mar;4 Suppl 1:47-8. doi: 10.1016/j.ijmyco.2014.10.046. Epub 2014 Dec 22.
Fluoroquinolones (FQ) are an essential component of current and new regimens for the treatment of tuberculosis (TB). The 2014 Global TB report indicates a FQ resistance rate of 17% amongst multidrug-resistant (MDR) strains of Mycobacterium tuberculosis (MTB) tested in 2013. There is, however, a paucity of FQ-resistance data from high burden countries. In this study the trend of FQ-resistance amongst MDR-MTB and non-MDR-MTB is analyzed over a four-and-a-half-year period (January 2010-July 2014).
This study was conducted at the Aga Khan University laboratory, a technical partner of the Pakistan National TB Program and part of the World Health Organization (WHO) Supra-national Laboratory Network for TB. The laboratory receives specimens from across the country through its peripheral collection units. MTB was isolated using standard methods. Susceptibility testing was performed using the agar proportion method with drug concentrations as recommended by Clinical Laboratory Institute Standards (CLSI). FQ susceptibilities were determined using ofloxacin (2μg/ml). MTB H37Rv was used as a control with each batch of susceptibility testing. MDR was defined as resistance to both isoniazid (0.2μg/ml) and rifampicin (1.0μg/ml).
During the study period 14,711 MTB strains were isolated. Of these, 6403 (43.5%) were MDR and 8308 were non-MDR. FQ resistance in MDR strains ranged between 54% and 58%. Amongst non-MDR MTB strains, FQ resistance increased from 214/2059 (10.3%) in 2010 to 180/1049 (17.1%) in 2014. The proportion of FQ mono-resistant TB strains averaged at 10.5% of the non-MDR isolates during this period.
FQ resistance in non-MDR-MTB strains with a considerable proportion of FQ mono-resistant strains in Pakistan is alarming. These data highlight the limited potential of empirical FQ usage for TB treatment in both MDR and non-MDR cases and the need to implement regular surveillance for FQ-resistance in MTB in the country. High FQ resistance amongst MTB isolates further emphasizes the importance of stewardship and the responsible use of FQs in particular, and antimicrobials in general in the country.
氟喹诺酮类药物(FQ)是目前及新的结核病(TB)治疗方案的重要组成部分。《2014年全球结核病报告》指出,2013年检测的耐多药(MDR)结核分枝杆菌(MTB)菌株中,FQ耐药率为17%。然而,高负担国家的FQ耐药数据匮乏。本研究分析了四年半期间(2010年1月至2014年7月)MDR-MTB和非MDR-MTB中FQ耐药性的趋势。
本研究在阿迦汗大学实验室进行,该实验室是巴基斯坦国家结核病项目的技术合作伙伴,也是世界卫生组织(WHO)结核病超国家实验室网络的一部分。该实验室通过其周边采集单位接收来自全国各地的标本。采用标准方法分离MTB。使用琼脂比例法按照临床实验室标准协会(CLSI)推荐的药物浓度进行药敏试验。使用氧氟沙星(2μg/ml)测定FQ敏感性。每批药敏试验均使用MTB H37Rv作为对照。MDR定义为对异烟肼(0.2μg/ml)和利福平(1.0μg/ml)均耐药。
在研究期间,共分离出14711株MTB菌株。其中,6403株(43.5%)为MDR,8308株为非MDR。MDR菌株中的FQ耐药率在54%至58%之间。在非MDR MTB菌株中,FQ耐药率从2010年的214/2059(10.3%)增至2014年的180/1049(17.1%)。在此期间,FQ单耐药结核菌株占非MDR分离株的比例平均为10.5%。
巴基斯坦非MDR-MTB菌株中的FQ耐药情况令人担忧,其中相当一部分为FQ单耐药菌株。这些数据凸显了在MDR和非MDR病例中经验性使用FQ治疗结核病的潜力有限,以及该国对MTB中FQ耐药性进行定期监测的必要性。MTB分离株中较高的FQ耐药率进一步强调了该国开展抗菌药物管理尤其是合理使用FQ以及一般抗菌药物的重要性。